Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Typical antipsychotic Stories

2009-05-19 06:57:00

SAN FRANCISCO, May 19 /PRNewswire/ -- Schizophrenia is one of the most disabling diseases,(1) and frequent relapses and rehospitalization as a result of the disease place enormous burdens on patients, caregivers and society.(2) According to two new studies, the use of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment (RLAT) may improve clinical and functional outcomes and reduce rates of rehospitalization among patients with schizophrenia. Results of the studies were presented this...

2009-05-18 12:30:00

Three-year data show olanzapine LAI safety findings consistent with oral olanzapine except for injection-related events INDIANAPOLIS, May 18 /PRNewswire-FirstCall/ -- Eli Lilly and Company presented today data on the short- and long-term efficacy and safety of olanzapine long-acting injection (LAI) in the treatment of adults with schizophrenia or schizoaffective disorder. Olanzapine LAI is an investigational formulation that combines the atypical antipsychotic Zyprexa(R) (olanzapine) with...

2009-05-06 16:53:29

The U.S. Food and Drug Administration has approved Fanapt tablets to treat adults with schizophrenia, a chronic, severe and disabling brain disorder. Schizophrenia can be a devastating illness requiring lifelong treatment and therapy, said Dr. Thomas Laughren, director of the FDA's division of psychiatry products. Medications for schizophrenia can ease many symptoms, allowing people to live more independent lives. The federal agency said Fanapt (iloperidone) is included in the atypical...

2009-01-15 05:05:00

INDIANAPOLIS, Jan. 15 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has reached resolution with the United States Attorney for the Eastern District of Pennsylvania (EDPA) and the Office of Consumer Litigation of the Department of Justice regarding the previously-reported government investigation into the company's past U.S. marketing and promotional practices for the antipsychotic medication Zyprexa(R) (olanzapine). Lilly has been cooperating...

2009-01-07 17:12:00

INDIANAPOLIS, Jan. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults. Lilly is continuing to work with the agency on the new drug application (NDA). The FDA does not require any additional clinical trials for the continued review of the NDA. Per the agency's...

2008-12-10 07:30:00

Results of Two Trials Identify Potential Initiation Dosing Regimen TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Paliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study presented today (1). Statistical significance was evidenced at all doses tested (25, 100, and 150 mg equivalent [eq.a]), when given every 4 weeks with a 150 mg eq. initiation dose. A separate...

2008-10-21 09:00:54

INDIANAPOLIS, Oct. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it is in advanced discussions to resolve the ongoing investigations led by the U.S. Attorney's Office for the Eastern District of Pennsylvania (EDPA) related to past U.S. marketing and promotional practices for its antipsychotic medication Zyprexa(R) (olanzapine). As a result, the company will record in the third quarter of 2008 a charge of $1.415 billion, or $1.29 per share. The Government's...

2008-10-09 18:00:12

Alkermes, Inc. (NASDAQ: ALKS) today announced that patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ((risperidone) Long-Acting Injection). The U.S. Food and Drug Administration (FDA) has approved a new injection site, the deltoid muscle in the arm, for RISPERDAL CONSTA for the treatment of patients with schizophrenia. RISPERDAL CONSTA was previously approved as a gluteal injection only. "RISPERDAL CONSTA serves an important role in the treatment of...

2008-10-07 09:00:55

INDIANAPOLIS, Ind., Oct. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it has resolved a multi-state investigation involving 32 states and the District of Columbia (DC) related to the sales, marketing and promotion of its antipsychotic medication Zyprexa(R) (olanzapine). "We believe all of the parties involved share an interest in putting this dispute behind us," said Robert A. Armitage, Lilly's senior vice president and general counsel. "From our standpoint, it's...

2008-09-26 06:00:12

INDIANAPOLIS, Sept. 26 /PRNewswire-FirstCall/ -- The Committee for Medicinal Products for Human Use (CHMP) has recommended European approval of Olanzapine Long-acting Injection (LAI), known in Europe by the trade name Zypadhera(TM), for maintenance treatment of adult patients with schizophrenia sufficiently stabilized during acute treatment with oral olanzapine, Eli Lilly and Company (LLY) announced today. The CHMP's positive opinion is now referred for final action to the European...